Marinus Pharmaceuticals (NASDAQ:MRNS) Earns Overweight Rating from Cantor Fitzgerald

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report)'s stock had its "overweight" rating restated by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $13.00 price objective on the biopharmaceutical company's stock.

Other equities analysts have also recently issued research reports about the stock. Truist Financial reissued a "buy" rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. StockNews.com upgraded shares of Marinus Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Monday, September 9th. HC Wainwright restated a "buy" rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. Finally, LADENBURG THALM/SH SH cut shares of Marinus Pharmaceuticals from a "buy" rating to a "neutral" rating in a research note on Wednesday, August 14th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $10.25.

Marinus Pharmaceuticals Stock Up 3.3 %

NASDAQ MRNS traded up $0.05 during mid-day trading on Monday, hitting $1.55. The company's stock had a trading volume of 488,406 shares, compared to its average volume of 1,137,950. The company has a current ratio of 2.28, a quick ratio of 2.15 and a debt-to-equity ratio of 5.68. Marinus Pharmaceuticals has a twelve month low of $1.05 and a twelve month high of $11.26. The firm has a market capitalization of $85.15 million, a price-to-earnings ratio of -0.59 and a beta of 1.13. The company's 50 day simple moving average is $1.35 and its 200 day simple moving average is $3.06.

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The company had revenue of $8.06 million during the quarter, compared to the consensus estimate of $9.05 million. During the same quarter in the prior year, the business earned ($0.61) EPS. Analysts anticipate that Marinus Pharmaceuticals will post -1.88 earnings per share for the current year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter valued at about $64,000. AQR Capital Management LLC boosted its stake in Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company's stock worth $37,000 after buying an additional 12,934 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Marinus Pharmaceuticals during the 2nd quarter valued at $206,000. Point72 DIFC Ltd bought a new position in shares of Marinus Pharmaceuticals during the second quarter valued at about $28,000. Finally, XTX Topco Ltd bought a new position in Marinus Pharmaceuticals during the 2nd quarter worth approximately $232,000. Institutional investors own 98.80% of the company's stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.